Mammalian target of rapamycin signaling inhibition ameliorates vascular calcification via Klotho upregulation
- PMID: 26061549
- DOI: 10.1038/ki.2015.160
Mammalian target of rapamycin signaling inhibition ameliorates vascular calcification via Klotho upregulation
Abstract
Vascular calcification (VC) is a major risk factor for cardiovascular mortality in chronic renal failure (CRF) patients, but the pathogenesis remains partially unknown and effective therapeutic targets should be urgently explored. Here we pursued the therapeutic role of rapamycin in CRF-related VC. Mammalian target of rapamycin (mTOR) signal was activated in the aortic wall of CRF rats. As expected, oral rapamycin administration significantly reduced VC by inhibiting mTOR in rats with CRF. Further in vitro results showed that activation of mTOR by both pharmacological agent and genetic method promoted, while inhibition of mTOR reduced, inorganic phosphate-induced vascular smooth muscle cell (VSMC) calcification and chondrogenic/osteogenic gene expression, which were independent of autophagy and apoptosis. Interestingly, the expression of Klotho, an antiaging gene that suppresses VC, was reduced in calcified vasculature, whereas rapamycin reversed membrane and secreted Klotho decline through mTOR inhibition. When mTOR signaling was enhanced by either mTOR overexpression or deletion of tuberous sclerosis 1, Klotho mRNA was further decreased in phosphate-treated VSMCs, suggesting a vital association between mTOR signaling and Klotho expression. More importantly, rapamycin failed to reduce VC in the absence of Klotho by using either siRNA knockdown of Klotho or Klotho knockout mice. Thus, Klotho has a critical role in mediating the observed decrease in calcification by rapamycin in vitro and in vivo.
Comment in
-
Klotho upregulation by rapamycin protects against vascular disease in CKD.Kidney Int. 2015 Oct;88(4):660-2. doi: 10.1038/ki.2015.223. Kidney Int. 2015. PMID: 26422620
-
No apparent link between serum Klotho and phosphate in human chronic kidney disease.Kidney Int. 2016 Jun;89(6):1399-400. doi: 10.1016/j.kint.2015.11.034. Kidney Int. 2016. PMID: 27181778 No abstract available.
Similar articles
-
Klotho upregulation by rapamycin protects against vascular disease in CKD.Kidney Int. 2015 Oct;88(4):660-2. doi: 10.1038/ki.2015.223. Kidney Int. 2015. PMID: 26422620
-
Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.J Vasc Surg. 2013 Feb;57(2):475-85. doi: 10.1016/j.jvs.2012.07.037. Epub 2012 Dec 21. J Vasc Surg. 2013. PMID: 23265586
-
Microsomal Prostaglandin E Synthase-1-Derived PGE2 Inhibits Vascular Smooth Muscle Cell Calcification.Arterioscler Thromb Vasc Biol. 2016 Jan;36(1):108-21. doi: 10.1161/ATVBAHA.115.306642. Epub 2015 Nov 5. Arterioscler Thromb Vasc Biol. 2016. PMID: 26543101
-
Angiotensin II blockade: how its molecular targets may signal to mitochondria and slow aging. Coincidences with calorie restriction and mTOR inhibition.Am J Physiol Heart Circ Physiol. 2015 Jul 1;309(1):H15-44. doi: 10.1152/ajpheart.00459.2014. Epub 2015 May 1. Am J Physiol Heart Circ Physiol. 2015. PMID: 25934099 Review.
-
[Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in klotho deficient environment].Clin Calcium. 2015 May;25(5):693-9. Clin Calcium. 2015. PMID: 25926573 Review. Japanese.
Cited by
-
Klotho, Aging, and the Failing Kidney.Front Endocrinol (Lausanne). 2020 Aug 27;11:560. doi: 10.3389/fendo.2020.00560. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32982966 Free PMC article. Review.
-
Klotho and Mesenchymal Stem Cells: A Review on Cell and Gene Therapy for Chronic Kidney Disease and Acute Kidney Disease.Pharmaceutics. 2021 Dec 21;14(1):11. doi: 10.3390/pharmaceutics14010011. Pharmaceutics. 2021. PMID: 35056905 Free PMC article. Review.
-
The controversy of klotho as a potential biomarker in chronic kidney disease.Front Pharmacol. 2022 Sep 21;13:931746. doi: 10.3389/fphar.2022.931746. eCollection 2022. Front Pharmacol. 2022. PMID: 36210812 Free PMC article. Review.
-
Similarities and Differences of Vascular Calcification in Diabetes and Chronic Kidney Disease.Diabetes Metab Syndr Obes. 2024 Jan 10;17:165-192. doi: 10.2147/DMSO.S438618. eCollection 2024. Diabetes Metab Syndr Obes. 2024. PMID: 38222032 Free PMC article. Review.
-
Klotho: An Emerging Factor With Ergogenic Potential.Front Rehabil Sci. 2022 Jan 6;2:807123. doi: 10.3389/fresc.2021.807123. eCollection 2021. Front Rehabil Sci. 2022. PMID: 36188832 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous